THE ROLE OF THE TRANSCRIPTION FACTOR GFI1 IN LEUKEMIA GENOME STABILITY AND EVOLUTION
EHA Learning Center, Daria Frank, 214636
VEGFC ANTIBODY TREATMENT: A NEW DIFFERENTIATION THERAPY FOR AML
EHA Learning Center, Kim Kampen, 214637
DISTINCT DNA METHYLATION PROFILES IN DIFFERENT CYTOGENETIC SUBGROUPS OF CHRONIC LYMPHOCYTIC LEUKEMIA: THE INTRIGUING CASE OF TRISOMY 12
EHA Learning Center, MARIA TSAGIOPOULOU, 214652
BIALLELIC INACTIVATION OF ATM AND BIRC3 IN DEL(11Q) CELLS DRIVES GENOMIC INSTABILITY AND TUMOR EXPANSION IN CRISPR/CAS9-GENERATED MODELS OF CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Miguel Quijada Alamo, 214653
CD20 IS A DIRECT REGULATOR OF B-CELL RECEPTOR SIGNALING IN THE MICROENVIRONMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Gabriela Pavlasova, 214654
CHARACTERIZATION OF PEDIATRIC T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH DNA METHYLATION STATUS
EHA Learning Center, Shunsuke Kimura, 215236
THE PHILADELPHIA-LIKE SUBTYPE IN CHILDREN WITH FIRST RELAPSE OF B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA: A STUDY OF THE GERMAN ALL-REZ BFM 2002 TRIAL
EHA Learning Center, Malwine Pogodzinski, 215237
HUMAN T CELL ACUTE LYMPHOBLASTIC LEUKEMIA DEVELOPS HYPOXIA-RELATED CHEMORESISTANCE THROUGH HIF1Α AND MTOR PATHWAY INTERACTIONS
EHA Learning Center, Lucine Fahy, 215238
THE CELL SURFACE PROTEIN VANIN-2 IDENTIFIES AGGRESSIVE SUBTYPES OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Virginia Rodriguez Martinez, 215253
NILOTINIB COMBINED WITH LOWER-INTENSITY CHEMOTHERAPY FOR FRONT-LINE TREATMENT OF YOUNGER ADULTS WITH PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): INTERIM ANALYSIS OF THE GRAAPH-2014 TRIAL
EHA Learning Center, Yves Chalandon, 215254
PEDIATRIC PATIENTS WITH ACUTE LEUKEMIA AND MLL REARRANGEMENT SHOW A DISTINCTIVE EXPRESSION PATTERN OF HISTONE DEACETYLASES
EHA Learning Center, Nerea Vega-Garcia, 215255
PHARMACOLOGIC INHIBITION OF CELLULAR METABOLIC PROCESSES IMPACTED BY AGING SENSITIZE ACUTE MYELOID LEUKEMIA (AML) CELLS TO THE NOVEL LIPOATE DERIVATIVE CPI-613
EHA Learning Center, Timothy Pardee, 215270
GENOMIC CHARACTERIZATION OF DIAGNOSTIC AND REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA SAMPLES THROUGH A NEXT GENERATION SEQUENCING (NGS) PANEL OF 62 GENES
EHA Learning Center, Diego Carbonell, 215271
THE CALCIUM BINDING PROTEIN S100A8/S100A9 COMPLEX IS ASSOCIATED WITH DRUG RESISTANCE IN ACUTE MYELOID LEUKEMIA
EHA Learning Center, Riikka Karjalainen, 215286
A HIGH RISK PEDIATRIC AML SUBTYPE PRESENTS A DIAGNOSTIC CHALLENGE-A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP AAML0531 STUDY
EHA Learning Center, Timothy P Singleton, 215288
SINGLE CENTRE REAL-LIFE EXPERIENCE OF HYPOMETHYLATING AGENTS WITH OR WITHOUT DLI AS SALVAGE THERAPY FOR ACUTE MYELOID LEUKEMIA RELAPSING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION.
EHA Learning Center, Davide Lazzarotto, 215303
CONSOLIDATION CHEMOTHERAPY PREVENTS RELAPSE BY INDIRECTLY REGULATING BONE MARROW ADIPOGENESIS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
EHA Learning Center, Hanyan Liu, 215304
INTRA-PATIENT DOSE-ESCALATION STUDY OF CRENOLANIB MAINTENANCE THERAPY IN PATIENTS WITH FLT3 MUTANT AML WHO HAD UNDERGONE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLO-HSCT)
EHA Learning Center, Betul Oran, 215319
CONSOLIDATION THERAPY WITH PONATINIB IN COMBINATION WITH CYTARABINE IN PATIENTS FOR FLT3-ITD ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION.
EHA Learning Center, Philippe Rousselot, 215320
ACALABRUTINIB IN COMBINATION WITH THE PI3Kδ INHIBITOR ACP-319 IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES.
EHA Learning Center, Paul M. Barr, 215335
TIME TO RELAPSE OF MANTLE CELL LYMPHOMA AFTER INTENSIVE HIGH DOSE CYTARABINE CONTAINING REGIMENS DEFINES PATIENTS RISK FOR DEATH: AN ANALYSIS FROM CENTERS OF THE FONDAZIONE ITALIANA LINFOMI
EHA Learning Center, Carlo Visco, 215336
THE ADDITION OF ROMIDEPSIN TO CHOEP FOLLOWED BY HIGH-DOSE CHEMOTHERAPY AND TRANSPLANTATION IS FEASIBLE IN UNTREATED PERIPHERAL T-CELL LYMPHOMAS: RESULTS OF PHASE IB FIL-PTCL13
EHA Learning Center, Annalisa Chiappella, 215351
A PHASE I, MULTICENTER, OPEN-LABEL DOSE-ESCALATION STUDY OF CC-122, A NOVEL CEREBLON-MODULATING AGENT, IN ADULT JAPANESE PATIENTS WITH ADVANCED NON-HODGKIN LYMPHOMA OR SOLID TUMOR
EHA Learning Center, Kazuhito Yamamoto, 215352
THALIDOMIDE USE IN HEREDITARY HEMORRHAGIC TELANGIECTASIA: A RETROSPECTIVE EVALUATION OF THE PATIENTS
EHA Learning Center, Mehmet Baysal, 215367
DIAGNOSIS AND MANAGEMENT OF ACQUIRED VON WILLEBRAND DISEASE. A SINGLE CENTER EXPERIENCE
EHA Learning Center, Cristina Santoro, 215368
MANAGEMENT OF PATIENTS WITH SEVERE APLASTIC ANAEMIA WHO ARE REFRACTORY TO PLATELET TRANSFUSIONS USING LEUKOCYTE CONCENTRATES
EHA Learning Center, jiali Huo, 215383
IRON OVERLOAD AND MANAGEMENT IN PATIENTS WITH DIAMOND BLACKFAN ANEMIA
EHA Learning Center, Sule Unal, 215384
DETIN: OVERCOMING TUMOR IN NORMAL CONTAMINATION.
EHA Learning Center, Amaro Taylor-Weiner, 215400
TRACKING THE MINOR CLONES IN OLIGOCLONAL CHRONIC LYMPHOCYTIC LEUKEMIA USING HIGH-THROUGHPUT IMMUNOPROFILING
EHA Learning Center, Kamila Stranska, 215401
EXPRESSION OF ANTIGENS INVOLVED IN THE FORMATION OF AN IMMUNOLOGICAL SYNAPSE IN CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Yulia Davydova, 215416
IDENTIFICATION OF NEWLY DIAGNOSED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AT HIGH RISK OF INFECTION OR TREATMENT THROUGH MACHINE LEARNING ALGORITHMS
EHA Learning Center, Carsten Niemann, 215417
PATIENT-SPECIFIC BCR-ABL1 GENOMIC FUSION ANALYSIS OF MINIMAL RESIDUAL DISEASE OF CML PATIENTS ELIGIBLE FOR TKI STOPPING SIGNIFICANTLY OUTPERFORMED MRNA DETECTION EITHER BY QPCR OR DIGITAL PCR
EHA Learning Center, Katerina Machova Polakova, 215432
TREATMENT-FREE REMISSION AFTER SECOND-STOP OF IMATINIB THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE
EHA Learning Center, Sukjoong Oh, 215433
COMBINED EMA-BINDING TEST AND OSMOTIC GRADIANT EKTACYTOMETRY SIGNIFICANTLY IMPROVE THE LABORATORY DIAGNOSIS OF HEREDITARY SPHEROCYTOSIS
EHA Learning Center, Andreas Glenthøj, 215449
PREVALENCE AND PREDICTORS OF LIVER FIBROSIS EVALUATED BY VIBRATION CONTROLLED TRANSIENT ELASTOGRAPHY (FIBROSCAN®) IN ADULT PATIENTS WITH TYPE 1 GAUCHER DISEASE
EHA Learning Center, Maria Domenica Cappellini, 215450
HIGH BASELINE FERRITIN IS ASSOCIATED WITH GRADE 2 CRS REQUIRING TOCILIZUMAB OR GRADE ≥ 3 CRS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH BB2121 ANTI-BCMA CAR T CELLS
EHA Learning Center, Jesus Berdeja, 215465
THE COMBINATION OF CD19/BCMA-DIRECTED CART CELLS INDUCED THERAPEUTIC RESPONSE AND REVERSIBLE COMPARTMENTAL CYTOKINE RELEASE SYNDROME CONFINED TO CEREBRAL REGION IN A PATIENT WITH CNS MULTIPLE MYELOMA
EHA Learning Center, Caixia Li, 215466
VERY LATE RELAPSES (VLRS) IN HODGKIN LYMPHOMA (HL) OCCURING ≥5 YEARS AFTER INITIAL TREATMENT WITH CHEMOTHERAPY ± RADIOTHERAPY (CT±RT): PATTERN OF RISK OVER 35 YEARS AND THE SIGNIFICANCE OF HISTOLOGY
EHA Learning Center, Theodoros Vassilakopoulos, 215481
BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE III OR IV HODGKIN LYMPHOMA: IMPACT OF CYCLE 2 PET RESULT ON MODIFIED PROGRESSION-FREE SURVIVAL
EHA Learning Center, Robert Chen, 215482
IBRUTINIB FOR THE TREATMENT OF BING-NEEL SYNDROME
EHA Learning Center, Jorge CASTILLO, 215497
IBRUTINIB MONOTHERAPY IN SYMPTOMATIC, TREATMENT-NAIVE PATIENTS WITH WALDENSTROM’S MACROGLOBULINEMIA.
EHA Learning Center, Steven Treon, 215498
THE DIAGNOSTIC UTILITY AND SENSITIVITY OF THE XPERT® MTB/RIF ASSAY IN DIAGNOSING MYCOBACTERIUM TUBERCULOSIS IN BONE MARROW ASPIRATE SPECIMENS
EHA Learning Center, Nadhiya Subramony, 215514
Clinical and microbiological profile of bloodstream infections in patients with hematological malignancies and febrile neutropenia (PS 1210).
EHA Learning Center, Haydee Bernard, 215515
IT TAKES A LOT OF IRON TO AVOID TRANSFUSION
EHA Learning Center, Magda Jabbar Al-Obaidi, 215531
PANCREATIC IRON LOADING IN EMOGLOBINOPATHIES.
EHA Learning Center, Alessia Pepe, 215532
AUTOPHAGY IN MYELODYSPLASTIC SYNDROMES: THE ROLE OF HIF-1A/REDD1 MOLECULAR PATHWAY
EHA Learning Center, Ioanna STERGIOU, 215547
AN OPEN-LABEL PHASE 1 STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DURVALUMAB IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AFTER TREATMENT WITH HYPOMETHYLATING AGENTS
EHA Learning Center, Guillermo Garcia-Manero, 215548
TLR4 SIGNALING DRIVES MESENCHYMAL STEM CELLS (MSC) COMMITMENT TO PROMOTE TUMOR MICROENVIRONMENT TRANSFORMATION IN MULTIPLE MYELOMA
EHA Learning Center, Cesarina Giallongo, 215564
BI-ALLELIC LOSS OF FAM46C BY CRISPR/CAS9 SYSTEM ENHANCES MYELOMA CELL GROWTH
EHA Learning Center, KANASUGI JO, 215565
TGFΒ INHIBITION IN COMBINATION WITH CHEMOTHERAPY REPAIRS EXISTING LYTIC BONE LESIONS IN A NOVEL PLATEAU PHASE MODEL OF MULTIPLE MYELOMA
EHA Learning Center, Andrew Chantry, 215580
MULTIPLE MYELOMA: SINGLE PLARFORM ABSOLUTE COUNT OF CIRCULATING PLASMA CELLS AT DIAGNOSIS CORRELATE WITH POOR PROGNOSIS PARAMETERS.
EHA Learning Center, Vittorio Emanuele Muccio, 215581
CARFILZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE IN TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PRELIMINARY RESULT OF SGHMM1 TRIAL, HIGH-RISK COHORT (NCT02217163)
EHA Learning Center, Chandramouli Nagarajan, 215596
WEEKLY CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): A PHASE 1B STUDY
EHA Learning Center, Noa Biran, 215597
NOVEL THERAPIES DIFFERENTIALLY IMPACT POLYCLONAL IMMUNOGLOBULIN RECOVERY IN MYELOMA PATIENTS: A LONGITUDINAL STUDY
EHA Learning Center, Mauricette Michallet, 215612
REAL-WORLD OUTCOMES IN TRANSPLANT INELIGIBLE NDMM PATIENTS: RESULTS FROM A LARGE UK COHORT
EHA Learning Center, FAOUZI DJEBBARI, 215613
AMPLICON NEXT-GENERATION SEQUENCING (NGS) OF REARRANGED IMMUNOGLOBULIN (IG) LOCI IS ADVANTAGEOUS FOR CLONAL MARKER IDENTIFICATION AND MINIMAL RESIDUAL DISEASE (MRD) DETECTION IN MULTIPLE MYELOMA (MM).
EHA Learning Center, Michaela Kotrová, 215628
A PHASE 1B STUDY USING THE COMBINATION OF SELINEXOR, DARATUMUMAB, AND DEXAMETHASOME IN MULTIPLE MYELOMA PATIENTS PREVIOUSLY EXPOSED TO PROTEASOME INHIBITORS AND IMMUNOMODULATORY DRUGS
EHA Learning Center, Cristina Gasparetto, 215629
BOARDING ON THE SECRETARY PATHWAY IS REQUIRED FOR THE ONCOGENIC PROPERTY OF MUTANT CALRETICULIN
EHA Learning Center, Marito Araki, 215643
PHARMACOLOGICAL INHIBITION OF IGF1R/IRS TARGETING STAT3/STAT5 SIGNALING HAS ANTI-NEOPLASTIC EFFECTS IN JAK2 V617F MYELOPROLIFERATIVE NEOPLASMS
EHA Learning Center, Jaqueline Fernandes, 215644
IN VIVO INHIBITION OF JAKS IN MYELOFIBROSIS IMPROVES MONOCYTES DIFFERENTIATION AND REACTIVATES PRO-INFLAMMATORY RESPONSE IN INFECTION-STIMULATED MONOCYTES
EHA Learning Center, Lucia Catani, 215645
LIMITATIONS OF PREVIOUS PROGNOSTIC MODELS FOR THROMBOSIS AND EXPLORATION OF MODIFIED MODELS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA
EHA Learning Center, Yoshinori Hashimoto, 215659
SERVICE EVALUATION OF PATIENTS WITH MYELOPROLIFERATIVE NEOPLASM AND SPLANCHNIC VEIN THROMBOSIS (MPN-SVT).
EHA Learning Center, Sarah Wharin, 215660
FAMILIAL MYELOPROLIFERATIVE NEOPLASMS: A SINGLE-INSTITUTION ANALYSIS OF 22 FAMILIES
EHA Learning Center, Margherita Maffioli, 215661
SPLENIC MARGINAL ZONE B-CELL LYMPHOMAS DEPENDS ON PROGRAMMED DEATH-LIGAND 1 FOR CLONAL EMERGENCE AND ARE CONTROLLED BY T-CELLS FOR PROLIFERATION RATE
EHA Learning Center, Nathalie FAUMONT, 215676
MECHANISMS CONFERRING RESISTANCE TO VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA AND MANTLE CELL LYMPHOMA
EHA Learning Center, Daniela Steinbrecher, 215677
CLINICAL, PATHOLOGICAL AND MOLECULAR STUDY OF 46 PATIENTS WITH A DIAGNOSIS OF CD5-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA.
EHA Learning Center, Vincent Allain, 215678
PREDICTIVE FACTORS FOR DEVELOPING SYSTEMIC LUPUS ERYTHEMATOSUS AFTER CHILDHOOD AUTOIMMUNE CYTOPENIA
EHA Learning Center, Nathalie Aladjidi, 215693
THE POLYMORPHISM OF CASPASE RECRUITMENT DOMAIN-CONTAINING PROTEIN 9 GENE MAY CONTRIBUTE TO RISK OF IMMUNE THROMBOCYTOPENIA
EHA Learning Center, Zi Sheng, 215694
FEATURES OF PRN1008, A BRUTON’S TYROSINE KINASE INHIBITOR, IN CLINICAL DEVELOPMENT FOR IMMUNE THROMBOCYTOPENIC PURPURA
EHA Learning Center, Steven Gourlay, 215695
THE IMPACT OF HIGH MOBILITY GROUP BOX 1 IN THE PATHOGENESIS OF IMMUNE THROMBOCYTOPENIA
EHA Learning Center, Mehmet Baysal, 215709
WHAT ARE THE UNDERLYING CAUSES AND CLINICAL CHARACTERISTICS OF CHILDREN WITH REACTIVE THROMBOCYTOSIS AT A KOREAN TERTIARY MEDICAL CENTER?
EHA Learning Center, Ye Jee Shim, 215710
STUDIES ON PLATELET FUNCTION IN A GROUP OF CLL PATIENTS DURING THE FIRST YEAR OF IBRUTINIB TREATMENT
EHA Learning Center, Bozena Sokolowska, 215712
VENETOCLAX IMPROVES QUALITY OF LIFE FOR PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Tara Cochrane, 215726
NO ASSOCIATION BETWEEN INDOOR RADON AND CHILDHOOD LEUKEMIA IN FRECCLE (FINNISH REGISTER-BASED CASE-CONTROL STUDY OF CHILDHOOD LEUKEMIA)
EHA Learning Center, Atte Nikkilä, 215727
CLARITHROMYCIN ADDED TO THE VCD REGIMEN CAUSES REDUCED HEALTH-RELATED QUALITY OF LIFE IN MULTIPLE MYELOMA PATIENTS
EHA Learning Center, Lene Kongsgaard Nielsen, 215728
IMPROVEMENT OF THE MULTIDISCIPLINARY MANAGEMENT OF SICKLE CELL DISEASE PATIENTS: IMPLEMENTATION OF A SICKLE CELL DISEASE PATIENT’S CLINICAL DATABASE: BELGIAN REGISTER OF SICKLE CELL DISEASE PATIENTS
EHA Learning Center, Beatrice Gulbis, 215743
VARIATIONS IN COMPLICATIONS RELATED TO VASO-OCCLUSIVE CRISES AND HYDROXYUREA USE IN PATIENTS WITH SICKLE CELL DISEASE: OBSERVATIONS FROM STUDIES IN THE USA, SPAIN AND THE GULF REGION
EHA Learning Center, Elena Cela, 215744
CORRELATION BETWEEN HEMOLYSIS AND HYPERCOAGULABILITY MARKERS AND EFFECTS OF HYDROXYUREA THERAPY IN SICKLE CELL PATIENTS
EHA Learning Center, Maria de Fátima Sonati, 215745
EFFICACY AND SAFETY OF DEFIBROTIDE BY VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) DIAGNOSTIC CRITERIA IN AN EXPANDED-ACCESS (T-IND) STUDY
EHA Learning Center, Selim Corbacioglu, 215759
PLASMA PRESEPSIN LEVEL IS A PREDICTIVE MARKER OF SEVERE ACUTE GVHD AFTER ALLO-HSCT: USEFULNESS AS A BIOMARKER OF ALLO-HSCT RELATED COMPLICATION
EHA Learning Center, Tatsuo Oyake, 215760
ROLE OF IFN-GAMMA IN IMMUNE-MEDIATED GRAFT FAILURE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Pietro Merli, 215761
REGRESSION TREE BASED MODEL FOR PREDICTING NON-RELAPSE MORTALITY IN AML PATIENTS ALLO-TRANSPLANTED IN FIRST COMPLETE REMISSION
EHA Learning Center, Anish Puliyayil, 215775
COMPARISON OF BUSULFAN/CYCLOPHOSPHAMIDE ALONE AND IN COMBINATION WITH THIOTEPA OR ANTI-THYMOCYTE GLOBULIN ON HEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOME AMONG BETA-THALASSEMIA PATIENTS
EHA Learning Center, Saqib Ansari, 215776
SECOND TRANSPLANT FOR PRIMARY GRAFT FAILURE , FOLLOWING HAPLOIDENTICAL GRAFTS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE
EHA Learning Center, SABRINA GIAMMARCO, 215777
LOW-DOSE INTERLEUKIN-2 RESTORING HUMAN REGULATORY T CELL FUNCTION IN VITRO AS A POTENTIAL APPLICATION FOR GVHD THERAPY AFTER TRANSPLANTATION
EHA Learning Center, Tzeon-Jye Chiou, 215791
HYPOFRACTIONATED TOTAL LYMPHOID IRRADIATION BY HELICAL TOMOTHERAPY AND HIGH DOSE CHEMOTHERAPY AS CONDITIONING FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY LYMPHOMA
EHA Learning Center, Fabio Guolo, 215792
THE RELATIONSHIP BETWEEN SELECTIVE PRE-TRANSPLANTATION IMMUNE PARAMETERS AND EARLY INFECTIONS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES UNDERGOING ASCT – PRELIMINARY REPORT
EHA Learning Center, Agnieszka Szymczyk, 215793
COMPREHENSIVE SCREENING FOR COEXISTING HETEROZYGOUS Α0-THALASSEMIA IN HEMOGLOBIN E TRAIT
EHA Learning Center, Piroonrut Wongprachar, 215808
ARE ALL DIRECT ORAL ANTICOAGULANTS EQUAL TO SAFETY AND EFFICACY?
EHA Learning Center, Begoña Navarro Almenzar, 215809
ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA AND ACUTE PANCREATITIS: VARIABLE AND RECIPROCAL PATHOPHYSIOLOGIC RELATIONSHIPS
EHA Learning Center, Qian (Janie) Qin, 215810
BACTERIAL CONTAMINANTS AND BIOFILMS EFFECT PLATELET ACTIVATION AND FUNCTION: IMPLICATIONS IN PLATELET TRANSFUSIONS
EHA Learning Center, Joels Wilson-Nieuwenhuis, 215824
ALLOIMMUNIZATION TO D AND NON-D RHESUS ANTIGENS INDUCED BY PLATELET TRANSFUSIONS
EHA Learning Center, Michael Daskalakis, 215825
MASSIVE TRANSFUSION PROTOCOLS - FRIEND OR FOE ?
EHA Learning Center, Moon Ley Tung, 215826
MIR-497~195 CLUSTER IS ASSOCIATED WITH FAVORABLE OUTCOME AND HAS A TUMOR SUPPRESSIVE FUNCTION IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Elena Boldrin, 215890
RELEVANCE OF PRE AND POST TRANSPLANT PET AND HASENCLEVER INDEX IN PATIENTS UNDERGOING AUTOLOGOUS TRANSPLANT FOR HODGKIN LYMPHOMA
EHA Learning Center, Siddharth Turkar, 215904
A REAL WORLD STUDY OF CLINICAL CHARACTERISTICS AND TREATMENT OUTCOME OF HODGKIN LYMPHOMA IN MALAYSIA: A SINGLE CENTER EXPERIENCE IN A RESOURCE LIMITED SETTING
EHA Learning Center, Tze Shin Leong, 215905
INTESTINAL COLONIZATION BY MULTIDRUG-RESISTANT GRAM-NEGATIVE PATHOGENS IN HEMATOLOGICAL PATIENTS: REAPPRAISAL OF SELECTIVE ORAL DECONTAMINATION
EHA Learning Center, Igor Stoma, 215906
HEMATOLOGICAL PHENOTYPES OF DIFFERENT ALPHA-THALASSAEMIA GENOTYPES CAUSING HYPOCHROMIC MICROCYTIC ANEMIA AT NEONATAL PERIOD
EHA Learning Center, thidarat suksangpleng, 215920
INVOLVEMENT OF LEUCOCYTE DERIVED EXTRACELLULAR VESICLES IN THE PROCOAGULANT STATE FOUND IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA-RELATED CONDITION
EHA Learning Center, Adeline Wannez, 215921
INCREASED PLATELET RESPONSE TO ENDOGENOUS AGONISTS, IN PRE-DIABETIC C57BL/6 MICE
EHA Learning Center, Zibusiso Mkandla, 215922

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings